Huntington's disease (HD) is a late-onset degenerative disorder of the central nervous system, caused by a dominantly inherited mutation in a gene on chromosome 4p. The identification of the trinucleotide repeat mutation responsible for this disorder has been an important step towards understanding
Zotepine in Huntington's disease
β Scribed by Raphael M. Bonelli; Gerald Niederwieser; Theresa Lahousen; Peter Hofmann
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 72 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0885-6222
- DOI
- 10.1002/hup.474
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The authors report a patient with Huntington's disease (HD) presenting with severe chorea. The motor scale of the unified HD rating scale (UHDRSβI) revealed 81 points. Motor function clearly improved with zotepine, until she reached an UHDRSβI of 34 points on day 7 of treatment. The patient was stable for at least 12 weeks. The improvement includes all seven categories of the UHDRSβI, especially chorea, gait and oral function. This is the first description of zotepine in HD. Our findings suggest that zotepine is useful in the treatment of HD chorea. Controlled trials of its use in HD would be welcome. Copyright Β© 2003 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
## Abstract Motor activity was quantitatively assessed over a period of 5 days using a wristβworn activity monitor in 14 patients with Huntington's disease (of whom 4 used neuroleptic drugs) and 14 age and sexβmatched healthy controls. Additionally, patients were rated for dementia, depression, cli
Two brothers with clinically definite adult Huntington's disease developed disabling myoclonus years after the first signs of the disease. Their electroencephalograms were consistent with a primary generalized epilepsy, although neither man had seizures. The myoclonus was controlled with valproic ac